key: cord-0905039-9gbdo60l
authors: Salari, Mehri; Etemadifar, Masoud; Zali, Alireza; Medghalchi, Aida; Tehrani Fateh, Sepand; Aminzade, Zahra; Bagheri Moghaddam, Sara
title: Seroprevalence of SARS‐CoV‐2 in Parkinson's Disease Patients: A Case–Control Study
date: 2021-03-17
journal: Mov Disord
DOI: 10.1002/mds.28580
sha: 1b3f3610183a69c8749aea47f658fab90f18f025
doc_id: 905039
cord_uid: 9gbdo60l

nan

A total of 90 subjects who were identified with PD and 97 healthy controls were included in the study. Table 1 presents the demographic, disease-associated, and COVID-19-related data. The difference in the proportion of variables is compared using Fisher's exact test, and the difference in mean IgG ratio in different groups is compared using the z score and Mann-Whitney U test depending on the distribution of data. About 25.56% of PD patients and 12.37% of controls tested positive for SARS-CoV-2 IgG antibody, and these proportions were significantly different (P < 0.05). The mean total IgG ratio was 1.53 AE 3.36 and 0.80 AE 2.17 in PD and control groups, respectively, and the difference was statistically significant (P < 0.01).

There was no statistical difference between the IgG ratio of PD patients and the control group who had direct contact with SARS-CoV-2-positive individuals (P > 0.05). Nevertheless, we found a statistically significant difference between the IgG ratio of PD patients and control group who had not direct contact with SARS-CoV-2-positive individuals (P < 0.00001). Moreover, the proportion of PD patients with positive IgG test who had no direct contact with Covid-19 patients was significantly higher than that of the same individuals in the control group (P < 0.05).

A study conducted in the United Kingdom supports our outcome 4 ; nevertheless, another study conducted in Italy showed that PD patients do not pose a higher risk of SARS-CoV2 infection, 5 but this study evaluated patients based on having an asymptomatic infection.

Therefore, the result of the current study indicates that PD patients can be more susceptible to Covid-19 infection. But more studies with higher sample sizes should be performed to confirm these results.

Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs. Dig Liver Dis

Strategic anti-SARS-CoV-2 serology testing in a low prevalence setting: the COVID-19 contact (CoCo) study in healthcare professionals

Impact of the COVID-19 pandemic on Parkinson's disease and movement disorders the COVID-19 pandemic is the PD population particularly vulnerable during the COVID-19 pandemic ? COVID-19 and neurological

Alzheimer's and Parkinson's diseases predict different COVID-19 outcomes, a UK Biobank study

COVID-19 in Parkinson's disease: report on prevalence and outcome

Seroepidemiological survey of the antibody for severe acute respiratory syndrome coronavirus 2 with neutralizing activity at hospitals: a crosssectional study in Hyogo prefecture